Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Obstetrics/Gynecology (Women’s Health) | Urology | Family Medicine
Disease Category: Urinary Incontinence
Location: United States, IN

Clinical Trial Details

Overview

Research Study Summary

Study to confirm the efficacy of Fesoterodine 4 mg compared to 8 mg.

Purpose

The purpose of this study is to compare the effectiveness of two doses of a drug called Fesoterodine and placebo (a substance that contains no active ingredient but looks identical to the study drug) for overactive bladder. In order to achieve this evaluation in an unbiased manner, you will be randomly assigned to one of 3 groups: Fesoterodine 4 mg, Fesoterodine 8 mg, or Placebo.

Patient Inclusion Criteria:

  • Male or female over the age of 18
  • Overactive bladder for over 6 months
  • Subject must LEAK

Patient Exclusion Criteria:

  • A neurological condition
  • History of lower urinary tract or pelvic surgery
  • History of IC, bladder stones, or urinary retention
  • Bladder outlet obstruction

To Learn more
Phase

4

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Kristen Willinger, Research Recruiter
First Urology, PSC. (formerly Metropolitan Urology and Allied Urology)
101 Hospital Blvd
Jeffersonville, IN 47130
Phone: (812) 206-8166
Fax: (812) 288-2612

View Map

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 180155

Date Last Changed: July 19, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.